29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial

IF 21 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI:10.1016/S1556-0864(25)00224-2

H. Lena , L. Paz-Ares , H. Harputluoglu , E. Wauters , S. Rossi , M. Ozguroglu , C. Helissey , G. Lo Russo , L. Greillier , M.A.N. Sendur , M. D’Arcangelo , H. Kobayashi , A. Martinez Bueno , O. Ozyilkan , M. Gumus , M. Celanovic , Y. Mekhloufi , E. Nadal

引用次数: 0

查看原文本刊更多论文

29P：评估tusamitamab ravtansine（一种靶向CEACAM5的抗体药物偶联物）在CEACAM5阴性或中度表达和高循环CEA的非鳞状NSCLC参与者中的应用：来自II期carmon - lc06试验的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.